Eli Lilly: encouraging results in breast cancer

(CercleFinance.com) - Eli Lilly today announced the results of a clinical trial evaluating Verzenio (abemaciclib), combined with an aromatase inhibitor (AI), versus an AI alone, as a treatment for postmenopausal patients with HR+ or HER2- advanced or metastatic breast cancer.


After eight years' follow-up, the study showed that women taking Verzenio + AI had a median overall survival (OS) of over 5.5 years, an increase of 13.1 months compared to the control arm in the intention-to-treat (ITT) population.

For women with metastases to visceral organs, the data showed a median OS of over five years, with an increase in median OS of 14.9 months in the Verzenio arm compared to the control arm.

This data further strengthens Verzenio's role in the survival of women with HR+, HER2- metastatic breast cancer, Lilly's Chief Medical Officer said.

Detailed results will be presented at the San Antonio Breast Cancer Symposium.


Copyright (c) 2023 CercleFinance.com. All rights reserved.